Vito W. Rebecca

Vito W. Rebecca

Auto-generated profile, based on publicly available information

Vito W. Rebecca

Johns Hopkins University 4 Department of Biochemistry and Molecular Biology Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
GSGaurav Sharma
Gaurav Sharma
RORani Ojha
Rani Ojha
ENEstela Noguera-Ortega
Estela Noguera-Ortega
VRVito W. Rebecca
Vito W. Rebecca
JAJohn Attanasio
John Attanasio
RARavi Amaravadi
Ravi Amaravadi
New strategies are needed to enhance the efficacy of anti–programmed cell death protein antibody (anti–PD-1 Ab) in cancer. Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of chloroquine derivatives like hydroxychloroquine (HCQ), enhances the antitumor efficacy of anti–PD-1 Ab in melanoma. The combination resulted in tumor growth impairment and improved survival in mouse models. Genetic suppression of core autophagy genes, but not Ppt1 , in cancer cells reduced priming and cytotoxic capacity of primed T cells. Exposure of antigen-primed T cells to macrophage-conditioned medium derived from macrophages treated with PPT1 inhibitors enhanced melanoma-specific killing. Genetic or chemical Ppt1 inhibition resulted in M2 to M1 phenotype switching in macrophages. The combination was associated with a reduction in myeloid-derived suppressor cells in the tumor. Ppt1 inhibition by HCQ, or DC661, induced cyclic GMP-AMP synthase/stimulator of interferon genes/TANK binding kinase 1 pathway activation and the secretion of interferon-β in macrophages, the latter being a key component for augmented T cell–mediated cytotoxicity. Genetic Ppt1 inhibition produced similar findings. These data provide the rationale for this combination in melanoma clinical trials and further investigation in other cancers.

17 July 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
BRBailey M. Robertson
Bailey M. Robertson
MFMitchell E. Fane
Mitchell E. Fane
AWAshani T. Weeraratna
Ashani T. Weeraratna
VRVito W. Rebecca
Vito W. Rebecca

1 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHeike Chauvistré
Heike Chauvistré
BSBatool Shannan
Batool Shannan
SDSheena M. Daignault-Mill
Sheena M. Daignault-Mill
RJRobert J. Ju
Robert J. Ju
DPDaniel Picard
Daniel Picard
ARAlexander Roesch
Alexander Roesch
Melanoma is a highly plastic tumor characterized by dynamic interconversion of different cell identities depending on the biological context. Melanoma cells with high expression of the H3K4 demethylase KDM5B (JARID1B) rest in a slow-cycling, yet reversible persister state. Over time, KDM5Bhigh cells can promote rapid tumor repopulation with equilibrated KDM5B expression heterogeneity. The cellular identity of KDM5Bhigh persister cells has not been studied so far, missing an important cell state-directed treatment opportunity in melanoma. Here, we have established a doxycycline-titratable system for genetic induction of permanent intratumor expression of KDM5B and screened for chemical agents that phenocopy this effect. Transcriptional profiling and cell functional assays confirmed that the dihydropyridine 2-phenoxyethyl 4-(2-fluorophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxylate (termed Cpd1) supports high KDM5B expression and directs melanoma cells towards differentiation along the melanocytic lineage and to cell cycle-arrest. The high KDM5B state additionally prevents cell proliferation through negative regulation of cytokinetic abscission. Moreover, treatment with Cpd1 promoted the expression of the melanocyte-specific tyrosinase gene specifically sensitizing melanoma cells for the tyrosinase-processed antifolate prodrug 3-O-(3,4,5-trimethoxybenzoyl)-(–)-epicatechin (TMECG). In summary, our study provides proof-of-concept for a dual hit strategy in melanoma, in which persister state-directed transitioning limits tumor plasticity and primes melanoma cells towards lineage-specific elimination.

24 April 2020 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
GAGretchen M. Alicea
Gretchen M. Alicea
VRVito W. Rebecca
Vito W. Rebecca

19 March 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SSSamanta Sharma
Samanta Sharma
TZTian Zhang
Tian Zhang
WMWojciech Michowski
Wojciech Michowski
VRVito W. Rebecca
Vito W. Rebecca
MXMin Xiao
Min Xiao
PSPiotr Sicinski
Piotr Sicinski
Significance: Melanomas are notorious due to their propensity to form lethal metastases. Currently, no treatments are available to stop the metastatic spread. We observed that in malignant melanomas, a protein called the cyclin-dependent kinase 5 (CDK5) is essential for melanoma metastasis. Using mouse and human melanoma cells, we demonstrated that in this tumor type CDK5 promotes the metastatic spread by directly phosphorylating a mesenchymal-type intermediate filament, vimentin. We found that a genetic shutdown of CDK5 in a mouse model of melanoma abrogated metastasis, while chemical inhibition of CDK5 kinase in mice carrying patient-derived tumors impeded the metastatic spread of tumor cells. Our results indicate that inhibition of CDK5 might represent a therapeutic strategy to block the metastatic dissemination of melanoma cells.

24 January 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
GAGretchen M. Alicea
Gretchen M. Alicea
VRVito W. Rebecca
Vito W. Rebecca